Marocaine Ste de Therapeutique SA

Marocaine Ste de Therapeutique SA has a basic capital structure with 7,661,900 shares outstanding, both basic and diluted, indicating no dilution from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company reported revenue of MAD 3.23 billion in the latest period. While profitability and return metrics are not available, the absence of valuation snapshot data prevents a direct comparison to industry benchmarks. The company's revenue scale suggests it is a mid-sized player in the pharmaceuticals industry.

Geographically and segment-wise, the company's exposure is not disclosed in the available data. There is no information on revenue concentration by region or product line, which limits the ability to assess diversification risk.

Growth trajectory is unclear due to the absence of historical revenue data and forward-looking guidance. The company's outlook for the current and next fiscal years is not quantified, and no numeric deltas are provided to assess growth potential.

Risk factors include the inability to assess liquidity risk, which could signal potential operational or financial constraints. The company is flagged for low dilution risk, but the lack of balance-sheet data and going-concern language in source documents raises uncertainty about its financial health.

Recent events, including filings and transcripts, are not disclosed in the available data. The company's ESG profile includes a Social pillar score of 34.92 and a Governance pillar score of 17.27, indicating room for improvement in both areas. The ESG controversies score of 100.00 suggests no major controversies were reported.